Circle Pharma’s first-in-class orally bioavailable macrocyclic cyclin A/B inhibitors highlighted in poster presentations at American Association for Cancer Research Annual Meeting
Data show activity across a wide range of human tumor cell lines Tumor regression observed in xenograft models of small cell lung cancer and ovarian